Table 2. Comparative features of BioNTainer (BioNTech) and Ntensify/Nfinity (Quantoom) modular mRNA vaccine manufacturing platforms.

Aspect	BioNTainer (BioNTech)	Ntensify/Nfinity (Quantoom)
Focus	Decentralized infrastructure	Process optimization and continuous flow
Scalability	Modular expansion	Scale-out with disposables (parallel batches)
Key innovation	Shipable GMP-compliant clean rooms	Modular equipment for in vitro transcription (Ntensify)
Cost efficiency	Reduces logistics and cold-chain costs	Cuts reagent uses and production costs by 60%
Target output	50 million doses/year (COVID-19 vaccine)	5 g mRNA/day (clinical scale)
Regulatory approach	Aligns with African Union and WHO standards	Standardized process for global GMP compliance

mRNA, messenger RNA; GMP, Good Manufacturing Practice; COVID-19, coronavirus disease 2019; WHO, World Health Organization.